Skip to main content
. 2020 Mar 17;11:327. doi: 10.3389/fphar.2020.00327

Table 1.

Clinical features at presentation of the examined patients with Type 3 BS.

cDNA (NM_000085.4)
and aminoacidic variation
Sex and age at onset Heterozygous/homozygous Serum K+ (mmol/L) Serum Mg2+
(mg/dl)
Serum HCO3- (mmol/L) Serum renin
(ng/ml/h)
Serum aldosterone
(pg/ml)
Serum creatinine
(mg/dl)
Urinary Ca2+
(mg/dl)
Clinical parameters
Patient I c.500G > T

p.Gly167Val
M, 2 years old Heterozygous with CLCNKB deletion 2,3 2,8 33,0 16,26 476 0,3 3,2 Growth delay, hematuria, polydipsia, polyuria, nephrocalcinosis
Patient II c.725C > A

p.Ala242Glu
F, 6 months Heterozygous with CLCNKB deletion 2,8 2,3 55,6 N.D. 800 0,2 7,84 Growth delay, polyhydramnios, asthenia
Patient III c.725C > A

p.Ala242Glu
F, 5 months Heterozygous with CLCNKA/CLCNKB Chimeric gene§ 3,0 1,8 55,0 264,6 30.9 1,34 0.6 Slight reduction of weight growth, vomit, anorexia, dehydration
Patient IV c.725C > A

p.Ala242Glu
F, 23 years old Homozygous 1,8 1,8 26,5 N.D. N.D. 1,3 N.D. Asthenia, polydipsia, cramps, tingling, abdominal pain, polyuria, heart problems, tetany, hyperpyrexia
Patient V c.865G > C

p.Gly289Arg
M, 5 months Homozygous 2,3 0,92 44,1 30 523,7 0,84 0,02 Slowing growth from the second month, vomit, polyuria, anorexia

§Deletion spanning from CLCNKA Exon 7 to CLCNKB Exon 6 included; HGVS nomenclature: chr1:g.(16353109_16353191) _(16374915_16374998)del.